Recent major advances in cancer immunotherapy, especially the immune checkpoint inhibitors targeting the PD-1/PD-L1 and CTLA-4 pathways, demonstrate remarkable curative benefits for some cancer patients. This evidence concerns the gene CTLA4 and cancer.